ALLURION TECHNOLOGIES, INC. (ALUR)

The Non-Surgical Approach to Weight Loss

Allurion Technologies manufactures and commercializes the Elipse, a swallowable gastric balloon designed to help patients lose weight without invasive surgery, general anesthesia, or hospitalization. The procedure is radically simple: a patient swallows a capsule containing a compressed balloon filled with fluid, a physician deploys it through the esophagus in minutes using endoscopic guidance, and the patient goes home the same day. After sixteen weeks, the balloon spontaneously deflates and passes naturally from the body. This non-surgical pathway offers substantial convenience and lower cost compared to traditional bariatric surgery, positioning Allurion in the intersection of medical devices and the rapidly expanding global weight-loss market.

Market Position and Competitive Landscape

The bariatric space is crowded but segmented: gastric surgery remains the gold standard for severe obesity, but newer GLP-1 receptor agonists have captured mainstream attention for moderate weight loss. Allurion’s balloon sits in the middle—less invasive than surgery, more potent than medications alone, and reversible. The company sells primarily through weight-loss clinics, bariatric centers, and endoscopy practices across North America, Europe, and Asia-Pacific. Clinical evidence demonstrating meaningful weight loss and acceptable safety has supported adoption, though physician familiarity and insurance reimbursement vary widely by market. Geographic expansion and increasing recognition of the temporary balloon as a legitimate treatment option remain key growth drivers.